Phase IV Multi-center Clinical Study of Kutai Concludes in Nanjing

REVIEW OF RESULTS CONFIRM SAFETY AND EFFICACY FOR ROOM TEMPERATURE STORAGE

NANTONG CITY, China, March 24 /PRNewswire-FirstCall/ -- Sinobiopharma, Inc.
(OTC Bulletin Board: SNBP) is pleased to announce that its patented version of
Cisatracurium besylate, a pre-surgical skeletal muscle relaxant marketed as
Kutai in China, has successfully concluded its Phase IV Clinical Study.

The multi-center Phase IV Clinical Study investigated the safety and
effectiveness of Kutai's use at room temperature. The after-market study,
supported by the National Multi-center Clinical plan, was concluded
successfully on September 2, 2008.

Kutai is a non-depolarizing skeletalmuscle relaxant for intravenous
administration. Compared to other neuromuscular blocking agents, it is
intermediate in its onset and duration of action.

More than 30 clinical experts from seven participating medical centers within
China gathered in Nanjing for a conference to review the results of the Phase
IV of the Kutai Multi-center clinical study project.

Ms. Xinming Wu, Chief anesthetist of No.1 Hospital of Chinese Peking
University Anesthesia Department, presided over the conference and delivered a
summary report of the Phase IV project. Xuejun Chen, Sinobiopharma's vice
president of sales was also in attendance and expressed Sinobiopharma's thanks
to the participating experts for their commitment to research on Kutai.

Sinobiopharma has established a highly specialized professional team of
clinical trial monitors as part of the project to keep close surveillance on
the patients. The manager of Sinobiopharma's Clinical Research Department, Mr.
Lei Wang, reported on the Phase IV project clinical monitoring outcomes.

The experts' consensus was that the Phase IV study established Kutai as safe
and effective for room temperature storage. The year-long clinical research
project showed no significant differences between Kutai and imported
Cisatracurium besylate, and no significant differences for Kutai safety and
effectiveness when stored at either room temperature or a lower temperature.

All the participating parties followed the study design and promote
inter-communication to ensure compliance with Good Clinical Practice (GCP).

About Sinobiopharma
Sinobiopharma, Inc. is a fully integrated and highly innovative biotechnology
company engaged in the research and development, manufacture and marketing of
biopharmaceutical products in China, the world's fastest growing
pharmaceutical market. Known as Dong Ying (Jiangsu) Pharmaceutical Co. Ltd. in
China, the Company's current therapeutic focus is on anesthesia-assisted
agents and cardiovascular drugs.

FORWARD LOOKING STATEMENTS
This news release may include "forward-looking statements" regarding
Sinobiopharma, Inc., and its subsidiaries, business and project plans. Such
forward looking statements are within the meaning of Section 27A of the
Securities Act of 1933, as amended, and section 21E of the United States
Securities and Exchange Act of 1934, as amended, and are intended to be
covered by the safe harbor created by such sections. Where Sinobiopharma, Inc.
expresses or implies an expectation or belief as to future events or results,
such expectation or belief is believed to have a reasonable basis. However,
forward-looking statements are subject to risks, uncertainties and other
factors, which could cause actual results to differ materially from future
results expressed, projected or implied by such forward-looking statements.
Sinobiopharma, Inc. does not undertake any obligation to update any
forward-looking statement, except as required under applicable law.

SOURCE Sinobiopharma, Inc.

Sinobiopharma, Inc. Investor Relations, 1-877-568-0188